Cell-based therapy for therapeutic lymphangiogenesis.
Identifieur interne : 006C34 ( Ncbi/Merge ); précédent : 006C33; suivant : 006C35Cell-based therapy for therapeutic lymphangiogenesis.
Auteurs : Shuqun Qi [République populaire de Chine] ; Jian PanSource :
- Stem cells and development [ 1557-8534 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Cellules souches embryonnaires (transplantation), Cellules souches pluripotentes induites (transplantation), Complications postopératoires (), Essais cliniques de phase I comme sujet, Facteur de croissance endothéliale vasculaire de type C (pharmacologie), Facteur de croissance endothéliale vasculaire de type C (usage thérapeutique), Facteurs de transcription (physiologie), Humains, Lymphangiogenèse (), Lymphangiogenèse (génétique), Lymphoedème (), Protéines suppresseurs de tumeurs (physiologie), Protéines à homéodomaine (physiologie), Prévision, Récepteur-3 au facteur croissance endothéliale vasculaire (déficit), Régulation de l'expression des gènes au cours du développement, Régénération, Souris, Souris knockout, Système lymphatique (physiologie), Transplantation de cellules souches mésenchymateuses (effets indésirables).
- MESH :
- déficit : Récepteur-3 au facteur croissance endothéliale vasculaire.
- effets indésirables : Transplantation de cellules souches mésenchymateuses.
- génétique : Lymphangiogenèse.
- pharmacologie : Facteur de croissance endothéliale vasculaire de type C.
- physiologie : Facteurs de transcription, Protéines suppresseurs de tumeurs, Protéines à homéodomaine, Système lymphatique.
- usage thérapeutique : Cellules souches embryonnaires, Cellules souches pluripotentes induites, Facteur de croissance endothéliale vasculaire de type C.
- Animaux, Complications postopératoires, Essais cliniques de phase I comme sujet, Humains, Lymphangiogenèse, Lymphoedème, Prévision, Régulation de l'expression des gènes au cours du développement, Régénération, Souris, Souris knockout.
English descriptors
- KwdEn :
- Animals, Clinical Trials, Phase I as Topic, Embryonic Stem Cells (transplantation), Forecasting, Gene Expression Regulation, Developmental, Homeodomain Proteins (physiology), Humans, Induced Pluripotent Stem Cells (transplantation), Lymphangiogenesis (drug effects), Lymphangiogenesis (genetics), Lymphatic System (physiology), Lymphedema (surgery), Mesenchymal Stem Cell Transplantation (adverse effects), Mice, Mice, Knockout, Postoperative Complications (surgery), Regeneration, Transcription Factors (physiology), Tumor Suppressor Proteins (physiology), Vascular Endothelial Growth Factor C (pharmacology), Vascular Endothelial Growth Factor C (therapeutic use), Vascular Endothelial Growth Factor Receptor-3 (deficiency).
- MESH :
- chemical , deficiency : Vascular Endothelial Growth Factor Receptor-3.
- chemical , pharmacology : Vascular Endothelial Growth Factor C.
- chemical , physiology : Homeodomain Proteins, Transcription Factors, Tumor Suppressor Proteins.
- adverse effects : Mesenchymal Stem Cell Transplantation.
- drug effects : Lymphangiogenesis.
- genetics : Lymphangiogenesis.
- physiology : Lymphatic System.
- surgery : Lymphedema, Postoperative Complications.
- chemical , therapeutic use : Vascular Endothelial Growth Factor C.
- transplantation : Embryonic Stem Cells, Induced Pluripotent Stem Cells.
- Animals, Clinical Trials, Phase I as Topic, Forecasting, Gene Expression Regulation, Developmental, Humans, Mice, Mice, Knockout, Regeneration.
Abstract
Lymphedema is a medically irreversible condition for which currently conservative and surgical therapies are either ineffective or impractical. The potential use of progenitor and stem cell-based therapies has offered a paradigm that may provide alternative treatment options for lymphatic disorders. Moreover, basic research, preclinical studies, as well as clinical trials have evaluated the therapeutic potential of various cell therapies in the field of lymphatic regeneration medicine. Among the available cell approaches, mesenchymal stem cells (MSCs) seem to be the most promising candidate mainly due to their abundant sources and easy availability as well as evitable ethical and immunological issues confronted with embryonic stem cells and induced pluripotent stem cells. In this context, the purpose of this review is to summarize various cell-based therapies for lymphedema, along with strengths and weaknesses of these therapies in the clinical application for lymphedema treatment. Particularly, we will highlight the use of MSCs for lymphatic regeneration medicine. In addition, the future perspectives of MSCs in the field of lymphatic regeneration will be discussed.
DOI: 10.1089/scd.2014.0390
PubMed: 25329370
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001248
- to stream PubMed, to step Curation: 001248
- to stream PubMed, to step Checkpoint: 001248
Links to Exploration step
pubmed:25329370Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cell-based therapy for therapeutic lymphangiogenesis.</title><author><name sortKey="Qi, Shuqun" sort="Qi, Shuqun" uniqKey="Qi S" first="Shuqun" last="Qi">Shuqun Qi</name><affiliation wicri:level="1"><nlm:affiliation>1 State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University , Chengdu, China .</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>1 State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University , Chengdu</wicri:regionArea><wicri:noRegion>Chengdu</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Jian" sort="Pan, Jian" uniqKey="Pan J" first="Jian" last="Pan">Jian Pan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25329370</idno><idno type="pmid">25329370</idno><idno type="doi">10.1089/scd.2014.0390</idno><idno type="wicri:Area/PubMed/Corpus">001248</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001248</idno><idno type="wicri:Area/PubMed/Curation">001248</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001248</idno><idno type="wicri:Area/PubMed/Checkpoint">001248</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001248</idno><idno type="wicri:Area/Ncbi/Merge">006C34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cell-based therapy for therapeutic lymphangiogenesis.</title><author><name sortKey="Qi, Shuqun" sort="Qi, Shuqun" uniqKey="Qi S" first="Shuqun" last="Qi">Shuqun Qi</name><affiliation wicri:level="1"><nlm:affiliation>1 State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University , Chengdu, China .</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>1 State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University , Chengdu</wicri:regionArea><wicri:noRegion>Chengdu</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Jian" sort="Pan, Jian" uniqKey="Pan J" first="Jian" last="Pan">Jian Pan</name></author></analytic><series><title level="j">Stem cells and development</title><idno type="eISSN">1557-8534</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Clinical Trials, Phase I as Topic</term><term>Embryonic Stem Cells (transplantation)</term><term>Forecasting</term><term>Gene Expression Regulation, Developmental</term><term>Homeodomain Proteins (physiology)</term><term>Humans</term><term>Induced Pluripotent Stem Cells (transplantation)</term><term>Lymphangiogenesis (drug effects)</term><term>Lymphangiogenesis (genetics)</term><term>Lymphatic System (physiology)</term><term>Lymphedema (surgery)</term><term>Mesenchymal Stem Cell Transplantation (adverse effects)</term><term>Mice</term><term>Mice, Knockout</term><term>Postoperative Complications (surgery)</term><term>Regeneration</term><term>Transcription Factors (physiology)</term><term>Tumor Suppressor Proteins (physiology)</term><term>Vascular Endothelial Growth Factor C (pharmacology)</term><term>Vascular Endothelial Growth Factor C (therapeutic use)</term><term>Vascular Endothelial Growth Factor Receptor-3 (deficiency)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules souches embryonnaires (transplantation)</term><term>Cellules souches pluripotentes induites (transplantation)</term><term>Complications postopératoires ()</term><term>Essais cliniques de phase I comme sujet</term><term>Facteur de croissance endothéliale vasculaire de type C (pharmacologie)</term><term>Facteur de croissance endothéliale vasculaire de type C (usage thérapeutique)</term><term>Facteurs de transcription (physiologie)</term><term>Humains</term><term>Lymphangiogenèse ()</term><term>Lymphangiogenèse (génétique)</term><term>Lymphoedème ()</term><term>Protéines suppresseurs de tumeurs (physiologie)</term><term>Protéines à homéodomaine (physiologie)</term><term>Prévision</term><term>Récepteur-3 au facteur croissance endothéliale vasculaire (déficit)</term><term>Régulation de l'expression des gènes au cours du développement</term><term>Régénération</term><term>Souris</term><term>Souris knockout</term><term>Système lymphatique (physiologie)</term><term>Transplantation de cellules souches mésenchymateuses (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Vascular Endothelial Growth Factor Receptor-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Homeodomain Proteins</term><term>Transcription Factors</term><term>Tumor Suppressor Proteins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Mesenchymal Stem Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphangiogenesis</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Récepteur-3 au facteur croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation de cellules souches mésenchymateuses</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lymphangiogenesis</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Lymphangiogenèse</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type C</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Facteurs de transcription</term><term>Protéines suppresseurs de tumeurs</term><term>Protéines à homéodomaine</term><term>Système lymphatique</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lymphatic System</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Lymphedema</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Embryonic Stem Cells</term><term>Induced Pluripotent Stem Cells</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cellules souches embryonnaires</term><term>Cellules souches pluripotentes induites</term><term>Facteur de croissance endothéliale vasculaire de type C</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials, Phase I as Topic</term><term>Forecasting</term><term>Gene Expression Regulation, Developmental</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Regeneration</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Complications postopératoires</term><term>Essais cliniques de phase I comme sujet</term><term>Humains</term><term>Lymphangiogenèse</term><term>Lymphoedème</term><term>Prévision</term><term>Régulation de l'expression des gènes au cours du développement</term><term>Régénération</term><term>Souris</term><term>Souris knockout</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphedema is a medically irreversible condition for which currently conservative and surgical therapies are either ineffective or impractical. The potential use of progenitor and stem cell-based therapies has offered a paradigm that may provide alternative treatment options for lymphatic disorders. Moreover, basic research, preclinical studies, as well as clinical trials have evaluated the therapeutic potential of various cell therapies in the field of lymphatic regeneration medicine. Among the available cell approaches, mesenchymal stem cells (MSCs) seem to be the most promising candidate mainly due to their abundant sources and easy availability as well as evitable ethical and immunological issues confronted with embryonic stem cells and induced pluripotent stem cells. In this context, the purpose of this review is to summarize various cell-based therapies for lymphedema, along with strengths and weaknesses of these therapies in the clinical application for lymphedema treatment. Particularly, we will highlight the use of MSCs for lymphatic regeneration medicine. In addition, the future perspectives of MSCs in the field of lymphatic regeneration will be discussed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25329370</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>23</Day></DateCreated><DateCompleted><Year>2016</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8534</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Stem cells and development</Title><ISOAbbreviation>Stem Cells Dev.</ISOAbbreviation></Journal><ArticleTitle>Cell-based therapy for therapeutic lymphangiogenesis.</ArticleTitle><Pagination><MedlinePgn>271-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/scd.2014.0390</ELocationID><Abstract><AbstractText>Lymphedema is a medically irreversible condition for which currently conservative and surgical therapies are either ineffective or impractical. The potential use of progenitor and stem cell-based therapies has offered a paradigm that may provide alternative treatment options for lymphatic disorders. Moreover, basic research, preclinical studies, as well as clinical trials have evaluated the therapeutic potential of various cell therapies in the field of lymphatic regeneration medicine. Among the available cell approaches, mesenchymal stem cells (MSCs) seem to be the most promising candidate mainly due to their abundant sources and easy availability as well as evitable ethical and immunological issues confronted with embryonic stem cells and induced pluripotent stem cells. In this context, the purpose of this review is to summarize various cell-based therapies for lymphedema, along with strengths and weaknesses of these therapies in the clinical application for lymphedema treatment. Particularly, we will highlight the use of MSCs for lymphatic regeneration medicine. In addition, the future perspectives of MSCs in the field of lymphatic regeneration will be discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Shuqun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University , Chengdu, China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cells Dev</MedlineTA><NlmUniqueID>101197107</NlmUniqueID><ISSNLinking>1547-3287</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102225">prospero-related homeobox 1 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467483">vascular endothelial growth factor C, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042583" MajorTopicYN="Y">Lymphangiogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008208" MajorTopicYN="N">Lymphatic System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25329370</ArticleId><ArticleId IdType="doi">10.1089/scd.2014.0390</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Pan, Jian" sort="Pan, Jian" uniqKey="Pan J" first="Jian" last="Pan">Jian Pan</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Qi, Shuqun" sort="Qi, Shuqun" uniqKey="Qi S" first="Shuqun" last="Qi">Shuqun Qi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006C34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 006C34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25329370
|texte= Cell-based therapy for therapeutic lymphangiogenesis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25329370" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |